Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2000-11-28
2010-06-29
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S178100, C424S277100, C514S001000, C436S064000
Reexamination Certificate
active
07744870
ABSTRACT:
Conjugated compounds which comprises an ST receptor binding moiety and a radiostable active moiety are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent, and a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radioactive, active moiety are disclosed. Methods of treating an individual suspected of suffering from metastasized colorectal cancer comprising the steps of administering to said individual a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent, and a therapeutically effective amount of a conjugated compound which comprises an ST receptor binding moiety and a radiostable active moiety or an ST receptor binding moiety and a radiostable active moiety are disclosed. Methods of radioimaging metastasized colorectal cancer cells comprising the steps of first administering to an individual suspected of having metastasized colorectal cancer cells, a pharmaceutical composition that comprises a pharmaceutically acceptable carrier or diluent, and conjugated compound that comprises an ST receptor binding moiety and a radioactive active moiety wherein the conjugated compound is present in an amount effective for diagnostic use in humans suffering from colorectal cancer and then detecting the localization and accumulation of radioactivity in the individual's body are disclosed.
REFERENCES:
patent: 4341763 (1982-07-01), Zygraich
patent: 4411888 (1983-10-01), Klipstein et al.
patent: 4499080 (1985-02-01), Duflot et al.
patent: 4584268 (1986-04-01), Ceriani et al.
patent: 4601896 (1986-07-01), Nugent
patent: 4659666 (1987-04-01), May et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4729893 (1988-03-01), Letcher et al.
patent: 4845200 (1989-07-01), Cullinan et al.
patent: 4849227 (1989-07-01), Cho
patent: 4867973 (1989-09-01), Goers et al.
patent: 4963263 (1990-10-01), Kauvar
patent: 4965188 (1990-10-01), Mullis et al.
patent: 5000935 (1991-03-01), Faulk
patent: 5057313 (1991-10-01), Shih et al.
patent: 5075216 (1991-12-01), Innis et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5133866 (1992-07-01), Kauvar
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5160723 (1992-11-01), Welt et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5183805 (1993-02-01), Lee et al.
patent: 5217869 (1993-06-01), Kauvar
patent: 5221736 (1993-06-01), Coolidge et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5237051 (1993-08-01), Garbers et al.
patent: 5252743 (1993-10-01), Barrett et al.
patent: 5270170 (1993-12-01), Schatz et al.
patent: 5271961 (1993-12-01), Mathiowitz et al.
patent: 5288514 (1994-02-01), Ellman
patent: 5324483 (1994-06-01), Cody et al.
patent: 5330892 (1994-07-01), Vogelstein et al.
patent: 5338665 (1994-08-01), Schatz et al.
patent: 5340474 (1994-08-01), Kauvar
patent: 5350741 (1994-09-01), Takada
patent: 5352775 (1994-10-01), Albertsen et al.
patent: 5366862 (1994-11-01), Venton et al.
patent: 5384261 (1995-01-01), Winkler et al.
patent: 5395750 (1995-03-01), Dillon et al.
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5405783 (1995-04-01), Pirrung et al.
patent: 5412087 (1995-05-01), McGall et al.
patent: 5420328 (1995-05-01), Campbell
patent: 5424186 (1995-06-01), Fodor et al.
patent: 5443816 (1995-08-01), Zamora et al.
patent: 5518888 (1996-05-01), Waldman
patent: 5585479 (1996-12-01), Hoke et al.
patent: 5593825 (1997-01-01), Carman et al.
patent: 5601990 (1997-02-01), Waldman
patent: 5731159 (1998-03-01), Waldman
patent: 5879656 (1999-03-01), Waldman
patent: 5928873 (1999-07-01), Waldman
patent: 5962220 (1999-10-01), Waldman
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6040167 (2000-03-01), Gluck et al.
patent: 6060037 (2000-05-01), Waldman
patent: 6087109 (2000-07-01), Waldman
patent: 6268159 (2001-07-01), Waldman et al.
patent: 6767704 (2004-07-01), Waldman
patent: 7097839 (2006-08-01), Waldman
patent: 2006/0014201 (2006-01-01), Waldman
patent: 2006/0269477 (2006-11-01), Waldman
patent: 0341661 (1989-11-01), None
patent: 04-503307 (1992-06-01), None
patent: 04-503945 (1992-07-01), None
patent: 06-503347 (1994-04-01), None
patent: 06-511466 (1994-12-01), None
patent: 63-501876 (1998-07-01), None
patent: 8402700 (1984-07-01), None
patent: WO 93/02708 (1993-02-01), None
patent: 8309512 (1984-08-01), None
Jain (Scientific American Jul. 1994).
Dillman (Annals of Internal Medicine, vol. 111, pp. 592-603, 1989).
Weiner (Seminars Oncology, vol. 26, No. 4, 1999, pp. 41-50).
de Sauvage et al., JBC, vol. 267, p. 6479-6482, Apr. 1992.
NCBI MeSH word search result.
Bremer, K.H., et al., “Safety and efficacy of radiopharmaceuticals,” Kristensen, K., et al. (eds.), Martinius Nijhoff, Dordrecht, the Netherlands, 1987, 43-50.
Dayhof,Nat. Biomed. Res. Found., 1978, Washington, D.C., 5, Supp. 3.
Hugues, M., et al., “Affinity purification of functional receptors forEscherichia coliheat-stable enterotoxin from rat intestine,”Biochemistry, 1992, 31, 12-16.
Kent, and Clark-Lewis in Synthetic peptides in biology and medicine, Alitalo, K., et al., (eds.),Science Publishers, Amsterdam, 1985, 295-358.
The Proteins, vol. II, 3rdEd., pp. 105-237, Neurath, H., et al. (eds.),Academic press, New York, NY, 1976.
Paxton, R.J., et al., “High-specific-activity 111 In-labeled anticarcinoembryonic antigen monoclonal antibody: improved method for the synthesis of diethylenetriaminepentaacetic acid conjugates,”Cancer Res., 1985, 45, 5694-5699.
Eildon, S.P., “Cytotoxicity and viability assays,” Animal Cell Culture: A Practical Approach, Freshney, R.I. (Ed.),IRL Press, Oxford, 1986, 183-216.
Almenoff, et al., “Ligand-based histochemical localization and capture of cells expressing heat-stable enterotoxin receptors,”Molecular Microbiology, 1993, 8, 865-873.
Bjorn, et al., “Antibody-pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitor,”Cancer Research, 1986, 46, 3262-3267.
Bjorn, et al., “Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins,”Cancer Research, 1985, 45, 1214-1221.
Bodansky, et al., “Peptide synthesis,” John Wiley and Sons, 2d Ed., 1976.
Burgess, et al., “Biological evaluation of a methanol-soluble, heat-stableEscherichia colienterotoxin in infant mice, pigs, rabbits and calves,”Infection and Immunity, 1978, 21, 526-531.
Cawley, et al., “Epidermal growth factor-toxin a chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic,”Cell, 1980, 22, 563-570.
Chan, et al., “Amino acid sequence of heat-stable enterotoxin produced byEscherichia colipathogenic for man,”J. Biol. Chem., 1981, 256, 7744-7746.
Chung, et al., “Enzymatically active peptide from the adenosine diphosphate-ribosylating toxin of pseudomonas aeruginosa,”Infection and Immunity, 1977, 16, 832-841.
Cumber, et al., “Preparation of antibody-toxin conjugates,”Methods in enzymology, 1985, 112, 207-225.
Currie, et al., “Guanylin: an endogenous activator of intestinal guanylate cyclase,”Proc. Natl. Acid. Sci. USA, 1992, 89, 947-951.
Dreyfus, et al., “Chemical properties of heat-stable enterotoxins produced by enterotoxigenicEscherichia coliof different host origins,”Infection and Immunity, 1983, 42, 539-548.
Eckelman, et al., “Comparison of99mTC and111in labeling of conjugated antibodies,”Nucl. Med. Biol., 1986, 13, 335-343.
Evans, et al., “Differencdes in the response of rabbit small intestine to heat-labile and heat-stable enterotoxins ofEscherichia coli,” Infection and Immunity, 1973, 7, 873-880.
Fitzgerald, et al., “Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis,”Cell, 1983, 32, 607-617.
Fitzgerald, et al., “Construction of immunotoxins using pseudomonas e
Helms Larry R.
Pepper Hamilton LLP
Thomas Jefferson University
Yao Lei
LandOfFree
ST receptor binding compounds and methods of using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ST receptor binding compounds and methods of using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ST receptor binding compounds and methods of using the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246369